Descreva o achado como no laudo. A resposta aponta uma das categorias publicadas, com a probabilidade e o trecho que a decide.
Categorias
Reescritas a partir da fonte e citadas
CR
1 de 4
Complete response
Complete Response: disappearance of all arterially enhancing (viable) tumor tissue, i.e. loss of any intratumoral arterial-phase hyperenhancement across all target and non-target HCC lesions.
verificadoModified RECIST (mRECIST) assessment for hepatocellular carcinomaPMC5771991 (Voizard et al., 'Locoregional Therapies for Hepatocellular Carcinoma and the New LI-RADS Treatment Response Algorithm') Table 4 'Overview of Response Criteria and Categories', mRECIST row ('Disappearance of any intratumoral APHE in all target and non-target lesions'); cross-checked PMC4624170 'Evaluation of treatment response' ('absence of arterially enhanced areas in all target lesions')
PR
2 de 4
Partial response
Partial Response: at least a 30% reduction in the sum of the diameters of the viable (arterially enhancing) portions of target lesions, referenced to the baseline sum.
verificadoModified RECIST (mRECIST) assessment for hepatocellular carcinomaPMC5771991 Table 4 mRECIST row ('>=30% decrease in the sum of diameters of viable target lesions'); reference is baseline per article text; cross-checked PMC4624170 'Evaluation of treatment response' ('>30% decrease' in sum of diameters of arterially enhanced areas vs baseline)
SD
3 de 4
Stable disease
Stable Disease: viable enhancing tumor that shrinks too little to qualify as partial response and grows too little to qualify as progressive disease.
verificadoModified RECIST (mRECIST) assessment for hepatocellular carcinomaPMC5771991 Table 4 mRECIST row ('Any cases that do not qualify for either partial response or progressive disease'); cross-checked PMC4624170 'Evaluation of treatment response' ('Neither PR nor PD')
PD
4 de 4
Progressive disease
Progressive Disease: at least a 20% increase in the sum of the diameters of viable (arterially enhancing) target lesions, or the appearance of one or more new lesions, or unequivocal progression of non-target disease.
verificadoModified RECIST (mRECIST) assessment for hepatocellular carcinomaPMC5771991 Table 4 mRECIST row ('>=20% increase in the sum of the diameters of viable target lesions or presence of one or more new lesions or unequivocal progression of existing non target lesions'); cross-checked PMC4624170 'Evaluation of treatment response' ('>20% increase' in sum of diameters of arterially enhanced areas)
Lógica de decisão estruturada
{
"categories": [
"CR",
"PR",
"SD",
"PD"
]
}
Referência, não é dispositivo médico. Confira a publicação primária vigente. O radiologista que assina o laudo continua autor e responsável.